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We previously reported that oesophageal squamous cell carcinoma (SCC) had a relatively high incidence of EGFR and HER-2
overexpression. Thus, anti-HER family targeting may become a promising approach to treat oesophageal SCC. In the present study,
we investigated (a) the distribution of EGFR and HER-2 expression in oesophageal SCC (n¼66) detected by immunohistochemistry
and (b) cetuximab- and/or trastuzumab-mediated biological activity (antiproliferative effect by the MTT assay, apoptosis-inducing
activity by the annexin V/propidium iodide assay, and antibody-dependent cellular cytotoxicity (ADCC) by the
51Cr-release assay)
against oesophageal SCC cell lines with various levels of EGFR and HER-2. Twelve of the 66 patients (18%) showed both EGFR- and
HER-2 expression. Out of both EGFR- and HER-2-positive cases, nine cases (75%) showed EGFR and HER-2 expression in
individually distinct regions. Furthermore, the combination of cetuximab and trastuzumab could induce synergistic antiproliferative
effects and additional ADCC activities against not all, but several oesophageal SCC cell lines with EGFR and HER-2 expression. The
combination of cetuximab and trastuzumab may be useful in the treatment of oesophageal SCC with EGFR and HER-2 expression.
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Oesophageal cancer is the sixth most frequent cause of cancer death
worldwide (Pisani et al, 1993). Most patients with oesophageal
cancer in Japan have squamous cell carcinoma (SCC), while most of
those in Western countries have adenocarcinoma. Despite improve-
ments in surgical techniques and perioperative management
(Akiyama et al,1 9 9 4 ;A n d oet al, 2000), and surgery combined
with chemotherapy (Ando et al, 2003) and/or radiotherapy (Ishikura
et al, 2003), the prognosis remains poor. Therefore, for oesophageal
SCC patients, novel therapies such as molecular-targeted therapy,
including small molecule inhibitors of tyrosine kinases or huma-
nised monoclonal antibodies, are very much needed.
The HER family of receptor tyrosine kinases consists of four
members: EGFR (HER-1), HER-2, HER-3, and HER-4. The HER
family-related signalling is reported to play an important role in
modulating cell proliferation, survival, migration, and differentia-
tion. Despite the large number of ligands so far identified for EGFR
and HER-3 and -4, no direct ligand for HER-2 has yet been
discovered. As HER-2 is the preferred heterodimerisation partner
for all other HER family members, increasing evidence suggests
that the primary function of HER-2 is as a co-receptor (Tzahar
et al, 1996; Graus-Porta et al, 1997). For example, when ligands
such as EGF bind to EGFR, EGFR is heterodimerised with HER-2,
leading to the subsequent activation of EGFR tyrosine kinase.
Overexpression of the HER family members has been identified
in a variety of human cancers such as gastrointestinal tract
(Ghaderi et al, 2002; Kimura et al, 2004), colorectal (Hayashi et al,
1994; Porebska et al, 2000; Ooi et al, 2004), breast (Suo et al, 2002;
Witton et al, 2003; Abd El-Rehim et al, 2004; DiGiovanna et al,
2005), lung (Hirsch et al, 2003), prostate (Di Lorenzo et al, 2002),
and bladder cancers (Chow et al, 2001; Wester et al, 2002), and is
correlated in a wide variety of tumours with the progression
(Yarden and Sliwkowski, 2001). In particular, we and others have
recently reported that the overexpression of EGFR of oesophageal
SCC, partially accounted for by gene amplification, is found in
50–70% (Itakura et al, 1994; Hanawa et al, 2006), and is indicative
of a poor prognosis (Ozawa et al, 1989; Yano et al, 1991).
Moreover, we showed that the overexpression of HER-2 in
oesophageal SCC was found in 30.3% (Mimura et al, 2005b).
These results indicated that oesophageal SCC shows a relatively
high incidence of EGFR and/or HER-2 overexpression.
There are several potential strategies for anti-HER family
targeting. Two anti-HER family-targeting therapies that have been
in clinical development are small-molecule EGFR tyrosine kinase
inhibitors such as gefitinib (Ranson et al, 2002; Fukuoka et al,
2003) and humanised antibodies against the HER family repre-
sented by cetuximab and trastuzumab (Herbst and Hong, 2002;
Needle, 2002). There are many mechanisms that are thought to
contribute to the antitumour activity of cetuximab and trastuzu-
mab, including a direct inhibition of EGFR tyrosine kinase activity
(Sato et al, 1983; Sliwkowski et al, 1999), the inhibition of cell cycle
progression (Wu et al, 1995; Peng et al, 1996), and increased levels
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sand activities of pro-apoptotic molecules (Wu et al, 1995; Cuello
et al, 2001; Liu et al, 2001). We recently reported the application of
trastuzumab for oesophageal SCC with the analysis of antibody-
dependent cellular cytotoxicity (ADCC) mediated by trastuzumab
(Mimura et al, 2005a). These results encourage us to apply a
combination therapy of cetuximab and trastuzumab for oesopha-
geal SCC, aiming at a synergistic effect. Thus, it is important to
identify how expressions of EGFR and HER-2 are distributed in
oesophageal SCC and if the combination of cetuximab and
trastuzumab has a synergistic antitumour effect against oesopha-
geal SCC.
In the present study, we investigated (a) the distribution of
EGFR and HER-2 expression in oesophageal SCC detected by
immunohistochemistry (IHC) and (b) the biological activity
(antiproliferative effect, apoptosis-inducing activity, and ADCC)
of cetuximab and trastuzumab against oesophageal SCC cell lines
with various levels of EGFR and HER-2.
MATERIALS AND METHODS
Patients
We examined 66 cases of primary oesophageal SCCs that were
histologically diagnosed and treated in the First Department of
Surgery, University of Yamanashi Hospital. The patients had not
received irradiation or chemotherapy before surgery. All patients
had undergone oesophagectomy with two-field (n¼39) or three-
field (n¼27) lymph node dissection between 1994 and 1999. The
patients were classified using the tumour node metastasis (TNM)
classification. The characteristics of the patients are shown in
Table 1. The study was approved by the Ethical Committee of the
University of Yamanashi, and written informed consent was
obtained from all individuals.
Cell lines and fresh tumour samples
Oesophageal SCC cell lines TE3, TE4, and TE5 were a kind gift
from Dr Nishihara (Institute of Development, Aging and Cancer,
University of Tohoku, Sendai, Japan). The oesophageal SCC cell
line KYSE50 was purchased from the Health Science Research
Resources Bank (Osaka, Japan). All cells were cultured in RPMI
1640 medium with 5% fetal bovine serum, 100unitsml
 1
penicillin, 100mgml
 1 streptomycin, and 2mmoll
 1 L-glutamine.
Primary solid tumour from oesophageal SCC patients (n¼6)
was isolated during surgery and was homogenised by mechanical
mincing. Then, cell mixtures were passed through a cell strainer
(Becton Dickinson Labware, Franklin Lakes, NJ, USA) and
suspended as a single-cell suspension. A single-cell suspension
derived from solid tumours and malignant pleural effusion was
purified by centrifugation with Ficoll–Paque (Pharmacia, Uppsala,
Sweden).
Chemicals and antibodies
Humanised mouse anti-human EGFR antibody, cetuximab
(Erbituxt), was purchased from Merck (Dietikon, Switzerland).
The anti-HER-2 monoclonal antibody trastuzumab (Herceptint)
and anti-CD20 mAb rituxan, which is an isotype-matched control
mAb, were purchased from Roche (Basel, Switzerland).
Immunohistochemistry
All resected oesophageal samples were immediately immersed
in 20% buffered neutral formalin, fixed overnight, and embedded
in paraffin according to standard procedures.
To detect EGFR, a paraffin-embedded tissue specimen was
sectioned at 4mm thickness and immunohistochemically stained
by the labelled streptavidin biotin (LSAB) method. After depar-
affinisation and rehydration, the sections were autoclaved in 0.01 M
citrate buffer (pH 7.0) at 1211C for 10min. Then, the sections were
cooled at room temperature for 60min, immersed in 3% hydrogen
peroxidase for 10min to block endogenous peroxidase activity,
and then washed in phosphate-buffered saline (PBS) for 5min.
To detect EGFR, mouse anti-human EGFR mAb (DakoCytomation,
Glostrup, Denmark) was used. The sections were incubated with
the antibody (diluted 1:40) for 24h at 41C in a moist chamber.
After washing three times with PBS for 5min, the sections
were reacted with the secondary antibody (biotinylated anti-mouse
antibody) for 30min at room temperature. Then the sections were
washed again three times with PBS for 5min after which they
were reacted with peroxidase-conjugated streptavidin for 30min at
room temperature. After this, the sections were washed again three
times with PBS for 5min and were reacted with a solution
containing 0.06mM 3,30-diaminobenzidine and 2mM hydrogen
peroxide in 0.05% Tris–HCl buffered at pH 7.6 for 10min. They
were then counterstained with haematoxylin for 30s. After
dehydrating with 60–100% isopropyl alcohol, penetrating, and
mounting, the sections were observed.
To detect HER-2, immunohistochemical staining was performed
using the HercepTest (DakoCytomation) according to the recom-
mendations of the manufacturer. Deparaffinised and rehydrated
tissue sections were incubated with the Epitope Retrieval Solution
in a hot water bath for 40min at 95–991C. Then, the sections were
cooled to room temperature for 20min, washed with Tris buffer
for 5min, and endogenous peroxidase was blocked with 3%
hydrogen peroxide for 5min. The primary antibody was rabbit
polyclonal antibody to human HER-2, which recognises an
intracytoplasmic part of HER-2, and the primary negative control
antibody was an immunoglobulin fraction of normal rabbit serum
at an equivalent protein concentration to the antibody to HER-2.
The sections were washed with TRIS buffer for 5min and
incubated with the primary antibody or the primary negative
Table 1 Clinical features of the patients (n¼66)
Age (years)
Mean 65.3
Range 45–81
Gender
Male 62
Female 4
Primary tumour
a
pTis 2
pT1a 8
pT1b 19
pT2 5
pT3 32
Lymph node metastasis
Negative 29
Positive 37
Histological grade
Well differentiated 16
Moderately differentiated 35
Poorly differentiated 15
Stage
a
09
I5
II 26
III 19
IVa 6
IVb 1
aThe grade of tumour and stages were defined according to the UICC (TNM)
classification.
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scontrol antibody at room temperature for 30min. After rewashing
with Tris buffer for 5min twice, the primary antibody was detected
by incubating at room temperature for 30min using the
visualisation reagents, dextran polymer conjugated with horse-
radish peroxidase and affinity-isolated goat anti-rabbit immuno-
globulin. Subsequently, following the rewashing with Tris buffer
for 5min twice, diaminobenzidine was added as a visualisation
reagent for 10min and sections were counterstained with
haematoxylin.
EGFR or HER-2 positivity in the IHC analysis was carried out by
three observers (YK, FM, and KK). The intensity of reactivity was
scored using four categories: negative, no discernible staining or
background type staining; 1þ, definite cytoplasmic staining and/
or equivocal discontinuous membrane staining; 2þ, unequivocal
membrane staining with moderate intensity; and 3þ, strong and
complete plasma membrane staining.
Flow cytometry
For the analysis of EGFR expression by flow cytometry, mouse
anti-human EGFR mAb (DakoCytomation) as the primary mAb
and an FITC-conjugated polyclonal rabbit anti-mouse mAb as the
secondary mAb (DakoCytomation) were used, and for the analysis
of HER-2 expression, a phycoerythrin-labelled anti-HER-2/neu
mAb (Becton Dickinson, San Jose, CA, USA) was used. As a
negative control for the primary mAb, mouse immunoglobulin
G1 mAb (Beckman-Coulter, Miami, FL, USA) was used.
Each step of the incubation with mAb was performed at 41C for
30min. After cells were washed twice in PBS, the stained cells were
analysed on a flow cytometer.
Fluorescence in situ hybridisation analysis
Fluorescence in situ hybridisation (FISH) analysis was carried out
using the PathVysion HER-2 DNA Probe Kit (Vysis, Downers
Grove, IL, USA). The HER-2/neu-SpectrumOrange probe contains
a DNA sequence specific for the HER-2 gene locus (17q11.2–q12).
The chromosome enumeration probe 17 (CEP 17)/SpectrumGreen
probe contains alpha-satellite DNA that hybridises to the D17Z1
locus (centromere region of chromosome 17). To determine the
copy number for chromosome 17, we used CEP 17 as the control.
Fluorescence in situ hybridisation procedures were conducted
according to the guidelines of the manufacturer, except the
removal of the protein from the tissue sections as described
previously (Takehana et al, 2002). In brief, deparaffinised and
dehydrated sections were incubated in 20% sodium bisulphate/2 
standard saline citrate (SSC) at 431C for 20min. After being
washed with SSC, sections were treated with proteinase K
(Boehringer-Mannheim, Mannheim, Germany) at 371C for 25min.
Subsequently, denaturation, hybridisation, and post-hybridisation
washing were carried out according to the manufacturer’s
protocol, and the sections were counterstained with 40,6-diami-
dine-20-phenylindole dihydrochloride (Oncor, Gaithersburg, MD,
USA). Fluorescence in situ hybridisation analysis was performed
using a fluorescence microscope (Olympus, Tokyo, Japan)
equipped with Triple Bandpass Filter sets (Vysis). Signals were
countered for at least 40 cancer nuclei per tumour. In accordance
with our previous studies with FISH, a cell was considered to show
amplification when a definite cluster or more than 10 orange
signals of HER-2 were observed (Takehana et al, 2002).
Antibody-dependent cell-mediated cytotoxicity assay
Peripheral blood mononuclear cells (PBMC) were separated from
peripheral blood obtained from healthy donors and oesophageal
SCC patients before treatment by centrifugation with Ficoll–Paque
(Pharmacia). After the target cells were labelled with 50mCi of
51Cr
for 60min, target cells (5 10
3well
 1) and PBMC from healthy
donors or oesophageal cancer patients as effector cells were
co-incubated at various effector/target ratios in 200ml of X-VIVO
medium in a 96-well U-bottomed plate in triplicate with indicated
doses of cetuximab or/and trastuzumab or a control antibody,
rituxan. After 6h of incubation, the radioactivity of the super-
natant (100ml) was measured with a g-counter. The percentage of
specific lysis¼100 (experimental c.p.m. spontaneous c.p.m.)/
(maximum c.p.m. spontaneous c.p.m.).
Apoptosis
Each cell line (2 10
5 cells) was incubated in 2ml of X-VIVO with
control mAb alone, cetuximab (0.5mgml
 1) alone, trastuzumab
(10mgml
 1) alone, and cetuximab in combination with trastuzu-
mab at 371C in a six-well plate. After incubation for 24h, apoptosis
in each cell line was measured by staining with FITC-conjugated
annexin-V and propidium iodide (PI) using a MEBCYTO
Apoptosis kit (MBL, Nagoya, Japan) following the manufacturer’s
recommendations.
MTT cell proliferation assay
Each cell line (2500 cells) was incubated in 200ml of X-VIVO with
indicated doses of cetuximab or/and trastuzumab, or a control
antibody in a 96-well flat-bottomed plate in triplicate. After
incubation for 96h at 371C, 50ml of MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, 2mgml
 1; Sigma, St Louis,
MO, USA) was added to each well and incubation was carried out
for 4h. Then, the supernatant was discarded and the crystal
products were eluted with DMSO (50mlwell
 1; Sigma). Colori-
metric evaluation was performed using a spectrophotometer at
570nm. The inhibition of proliferation was shown as % cell growth
inhibition induced by cetuximab or/and trastuzumab in compar-
ison with that induced by control mAb.
Survival analysis
Actuarial overall survival rates were analysed by the Kaplan–Meier
method, and survival was measured in months from operation to
death or the last review. The log-rank test was applied to compare
the two groups.
Statistics
To evaluate significant differences between groups, Student’s t-test
was performed. Significance was considered at Po0.05.
RESULTS
Frequencies and patterns of EGFR and HER-2 expression
in oesophageal SCC
Sixty-six oesophageal SCC tumours were examined for both EGFR
and HER-2 expression in serial sections by IHC. EGFR-positive
expression was observed in 22 cases (33%), while HER-2-positive
expression was noted in 20 cases (31%). Both EGFR and HER-2
expressions in the same patients were observed in 12 cases (18%)
(Figures 1 and 2), in which expressions of both EGFR and HER-2
were seen in the same tumour regions in two cases (Figure 1), and
EGFR and HER-2 expressions were seen in individually distinct
regions in nine cases (Figure 2). The data of EGFR and HER-2
expression in oesophageal SCC indicated that 45% of the patients
showed either EGFR or HER-2 expression, and 18% of the patients
showed both EGFR and HER-2. Of both EGFR- and HER-2-positive
cases, 75% showed EGFR and HER-2 expression in individually
distinct regions.
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sFurthermore, distribution of the grading of IHC for EGFR and
HER-2 is shown in Table 2, indicating that there were variable
patterns in their grading.
Oesophageal SCC patient survival in relation to EGFR and
HER-2 expression
There was a tendency that the survival rate of patients with both
EGFR (þ) and HER-2 (þ) was lower than those with EGFR ( )
and HER-2 ( ), although it was not significant (Figure 3).
Synergistic antiproliferative effect of cetuximab and
trastuzumab against oesophageal SCC
We have reported previously six different oesophageal SCC cell
lines with variable expressions of HER-2 (Mimura et al, 2005a). Of
these, TE3 was selected as a low-HER-2- and high-EGFR-
expressing cell, KYSE50 and TE5 as a moderate-HER-2- and
moderate-EGFR-expressing cell, and TE4 as a high-HER-2- and
low-EGFR-expressing cell in the present study analysed by flow
cytometry (Table 3). In FISH analysis, HER-2 gene amplification
was seen in TE4 (Table 3), and polysomy, in which cancer nuclei
showed more than three HER-2 signals accompanied with the same
number of centromere 17 signals, was seen in TE3, TE5, and
KYSE50 (Table 3). There was no significant quantitative correla-
tion between HER-2 and EGFR expression analysed by flow
cytometry in six different oesophageal SCC cell lines (data not
shown).
EGFR (+) HER-2 (–)
HER-2 (+) EGFR (–)
A
C
B
D
Figure 2 Immunohistochemical staining of EGFR and HER-2 in
oesophageal SCC. In oesophageal SCC, EGFR and HER-2 expressions
were evaluated by IHC in the serial sections ( 100). The region with
EGFR-positive expression (A) was negative for HER-2 (B) in the same
tumour. On the contrary, the region with HER-2-positive expression (D)
was negative for EGFR (C) in the same tumour.
Table 2 Grading patterns of HER-2 and EGFR expression in
oesophageal SCC (n¼66)
IHC scores of HER-2
Total 3+ 2+ 1+ 0
IHC scores of EGFR 3+ 2 3 1 5 11
2+ 0 0 4 4 8
1+ 1 0 1 1 3
0 0 3 5 36 44
Total 3 6 11 46 66
IHC¼immunohistochemistry; SCC¼squamous cell carcinoma.
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Figure 3 Survival curves of the patients with oesophageal SCC in
relation to EGFR and HER-2 expression. Actuarial overall survival rates
were analysed by the Kaplan–Meier method, and survival was measured in
months from operation to death or the last review.
EGFR (+)×100 HER-2 (+)×100
AB
Figure 1 Immunohistochemical staining of EGFR and HER-2 in
oesophageal SCC. In oesophageal SCC, EGFR and HER-2 expressions
were evaluated by IHC in the serial sections. Representative stainings for
EGFR (A) and HER-2 (B) are shown, and both expressions were seen in
the same regions of the oesophageal SCC tumour ( 100).
Table 3 Antitumour effect against oesophageal cancer cell lines
TE3 TE5 KYSE50 TE4
EGFR and HER-2 status
EGFR FACS (MFI) 211 150 114 76
HER-2 FACS (MFI) 46 113 83 258
HER-2 FISH Polysomy Polysomy Polysomy Cluster
% Inhibition of growth (MTT)
Ce (0.5mgml
 1) 55.171.1 21.771.3 33.573.8  3.875.2
Tra (10mgml
 1)  2.275.4 2.875.4 16.870.7 9.773.6
Ce+Tra 74.372.4 32.972.2 39.874.1 4.173.1
Apoptosis (%)
Medium 4.771.4 3.270.6 7.870.3 8.270.7
Medium+Ce (0.5mgml
 1) 8.770.6 5.070.5 9.170.7 9.871.6
Medium+Tra (10mgml
 1) 4.270.6 2.570.1 8.572.3 10.070.7
Medium+Ce+Tra 13.772.3 5.370.3 11.170.5 11.572.2
Cet¼cetuximab; FACS¼fluorescence-activated cell sorting; FISH¼Fluorescence in
situ hybridisation; MFI¼mean fluorescence intensity; MTT¼3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide; Tra¼trastuzumab.
Cetuximab and trastuzumab for oesophageal SCC
Y Kawaguchi et al
497
British Journal of Cancer (2007) 97(4), 494–501 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sNext, we examined HER-2 and EGFR expression in freshly
isolated tumours (primary tumour and malignant pleural effusion)
derived from six different oesophageal SCC patients. Representa-
tive flow data revealed the weak or moderate, but significant levels
of HER-2 and EGFR expression in comparison with oesophageal
SCC cell lines analysed by flow cytometry (Figure 4).
To examine the antiproliferative activity of cetuximab and/or
trastuzumab, the MTT assay was performed. Of note, synergistic
antiproliferative effects of cetuximab and trastuzumab were
observed in TE3 (HER-2 low and EGFR high), while an additional
antiproliferative effect was seen in KYSE50 (Table 3). Furthermore,
the synergistic antiproliferative effects were confirmed in variable
dose combinations of cetuximab and trastuzumab, and the same
effects were also observed in the different oesophageal SCC TE5
(HER-2 moderate and EGFR –moderate; Figure 5). To examine the
apoptosis-inducing activity of cetuximab and/or trastuzumab, the
annexin–PI assay was performed. There were marginal levels of
apoptosis induced by cetuximab and/or trastuzumab (Table 3).
Cetuximab- and/or trastuzumab-mediated ADCC for
oesophageal SCC
Next, we investigated whether the combination of cetuximab and
trastuzumab induces synergistic effects in ADCC against oesopha-
geal SCC with different levels of EGFR and HER-2. Representative
data with several dose combinations of cetuximab and trastuzu-
mab induced very marginal enhancements of ADCC derived from
healthy donor’s PBMC against oesophageal SCC (Figure 6).
Summarised data using PBMC from healthy donors (n¼5)
and oesophageal cancer patients (n¼5) showed that marginal
additional effects of cetuximab and trastuzumab were found only
in ADCC for TE3, while no significant effects for KYSE50 or TE4
were seen (Figure 7).
DISCUSSION
The present study contains important findings relevant to EGFR-
and HER-2-targeted therapy for oesophageal SCC. First, 30 out of
66 patients (45%) showed either EGFR or HER-2 expression, and
18% of the patients showed both EGFR and HER-2. Second, the
combination of cetuximab and trastuzumab could induce syner-
gistic antiproliferative effects against not all, but several oesopha-
geal SCC cell lines with EGFR and HER-2 expression.
Activation of the HER family triggers a network of signalling
pathways related to tumour cell proliferation and migration
(Yarden and Sliwkowski, 2001). A number of strategies against
EGFR and HER-2 have been developed, including mAbs and small-
molecule kinase inhibitors (Mendelsohn and Baselga, 2003). There
have been data from clinical trials demonstrating the results of
applying anti-EGFR tyrosine kinase inhibitors (gefitinib or
erlotinib) to oesophageal adenocarcinoma (Dragovich et al, 2006;
Kwak et al, 2006), indicating that erlotinib may be active in
patients with oesophageal adenocarcinoma and the useful
molecular marker will be needed to predict the therapeutic
response.
Although there is no previous report describing the clinical
application of cetuximab to oesophageal SCC patients, it has been
shown that cetuximab-induced antitumour activity did not
correlate directly with the levels of EGFR expression in human
TE3
HER-2 EGFR
Primary tumour Primary tumour
EGFR expression
C
e
l
l
 
c
o
u
n
t
HER-2 expression
TE3
TE4 TE4
Malignant pleural effusion Malignant pleural effusion
Control Control
Control Control
Control Control
Control Control
Figure 4 The degree of EGFR and HER-2 expression on oesophageal
SCC cell lines and freshly isolated SCC tumours. EGFR and HER-2
expression was evaluated by flow cytometric analysis on oesophageal SCC
cell lines and freshly isolated SCC tumours derived from two different
patients.
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Figure 5 Synergistic antiproliferative effects of cetuximab and trastuzu-
mab for oesophageal SCC cell lines. The oesophageal SCC lines, TE3
(HER-2 low and EGFR high) and TE5 (HER-2 moderate and EGFR
moderate), were analysed by the MTT assay in various dose combinations
of cetuximab and trastuzumab. The inhibition of proliferation was shown as
% cell growth inhibition induced by cetuximab and/or trastuzumab in
comparison with that induced by control mAb.
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stumour xenograft models (Wild et al, 2006). These observations
suggest that molecular events other than EGFR levels are true
determinants of in vivo responsiveness to EGFR-targeted therapy,
and further investigation is necessary to find out the factor that
affects the antitumour effect of cetuximab and gefitinib.
We recently reported that treatment with trastuzumab could
induce antitumour activities against oesophageal SCC with HER-2
expression, mainly mediated by ADCC activity. However, the
trastuzumab-mediated ADCC activities reflected the degree of
HER-2 expression, and furthermore, patients’ PBMC-derived
ADCC was impaired in comparison to healthy donors. These
results suggested that some modalities aiming at enhancing
the trastuzumab-mediated antitumour effect are needed for the
successful treatment of oesophageal SCC with trastuzumab.
One possible strategy to enhance antitumour activities is a
combination of trastuzumab with anti-EGFR mAb, cetuximab.
With regard to the expression of HER-2 and EGFR on
oesophageal SCC, EGFR-positive tumours were observed in 35%
of patients with oesophageal SCC, and HER-2-positive tumours
were observed in 31% of them in the present study, in line
with previous reports (Mimura et al, 2005b). This result was the
high-end of the data in literature showing HER-2 expression in
oesophageal SCC varying between 0 and 31% (Sunpaweravong
et al, 2005), in which the different rate of HER-2 expression seems
to be due to the different criteria for evaluating the results.
Importantly, both EGFR- and HER-2-positive tumours were
observed in 18% of all patients, out of which 75% showed EGFR
and HER-2 expression in individually distinct regions. These in
vivo data suggest that combined targeting with EGFR and HER-2
may result in an additional clinical response in patients with both
EGFR and HER-2 expression.
Both antibodies were reported to have functions including
internalisation and downregulation of the receptors (Fan et al,
1994; Goldstein et al, 1995; Sliwkowski et al, 1999), inhibition of
tyrosine kinase activity (Sato et al, 1983), inhibition of cell cycle
progression (Wu et al, 1995; Peng et al, 1996), and increased levels
and activities of pro-apoptotic molecules (Wu et al, 1995; Liu et al,
2001). In addition, we recently reported that trastuzumab could
induce ADCC activity for oesophageal SCC (Mimura et al, 2005a)
or gastric cancer (Kono et al, 2002).
It has been shown that treatment with cetuximab or trastuzu-
mab for breast cancer cells promoted the specific induction of
pro-apoptotic molecules and resulted in the upregulation of
chemosensitisation (Real et al, 2005). Furthermore, it has been
reported that EGFR-HER-2 heterodimers are rate-limiting in the
EGF-mediated proliferation of tumour cells (Hsieh et al, 2000).
These results suggested that EGFR and HER-2 may interact with
each other and lead to effective antitumour activity. As a novel and
important finding in the present study, the combination of
cetuximab and trastuzumab could induce synergistic antiproli-
ferative effects against several oesophageal SCC cell lines with
TE4 (HER-2-high, EGFR-low)
KYSE50 (HER-2-moderate, EGFR-moderate)
TE3 (HER-2-low, EGFR-high)
E : T=40 : 1
E : T=40 : 1
E : T=40 : 1
Cetuximab (g ml
–1) 0.5 0 0 0.5 0.5 55 5  
Trastuzumab (g ml
–1) 0 0 10 10 100 100 10 100
%
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Figure 6 Cetuximab- and/or trastuzumab-mediated ADCC for oeso-
phageal SCC cell lines. Oesophageal SCC cell lines with various levels of
EGFR and HER-2 expression (TE3, KYSE50, and TE4) were analysed for
ADCC derived from healthy donor’s PBMC in various dose combinations
of cetuximab, trastuzumab, and control mAb by the 6-h
51Cr release assay.
E:T, effector/target ratios.
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Figure 7 Cetuximab- and/or trastuzumab-mediated ADCC for oeso-
phageal SCC in healthy donors and oesophageal SCC patients.
Oesophageal SCC cell lines with various levels of EGFR and HER-2
expression were analysed for ADCC by healthy donors’ PBMC and
patients’ PBMC in the presence of cetuximab (0.5mgml
 1) and/or
trastuzumab (10mgml
 1) or control mAb (1mgml
 1) by the 6-h
51Cr
release assay. Summarised data from healthy donors’ PBMC (n¼5) and
oesophageal cancer patients’ PBMC (n¼5) are shown. E:T, effector/target
ratios.
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HER-2 expression in oesophageal SCC cell lines was not the only
factor predicting the sensitivity to cetuximab and trastuzumab,
since SCC cell lines, such as KYSE50 and TE5, with almost the
same level of EGFR and HER-2 –expression, had a different
amount of synergistic, antiproliferative effects with cetuximab and
trastuzumab. Further investigation is necessary to elucidate the
factors that affect the antitumour effect of cetuximab and
trastuzumab combination.
In conclusion, the combination of cetuximab and trastuzumab
could induce synergistic antiproliferative effects and additional
ADCC activities against several oesophageal SCC cells. A better
understanding of the detailed mechanisms involved in EGFR and/
or HER-2 may help identify new therapeutic targets in oesophageal
SCC.
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